{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:52:02Z","timestamp":1786978322644,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluated whether adding sodium\u2010glucose cotransporter\u20102 inhibitors (SGLT2i) and\/or glucagon\u2010like peptide\u20101 receptor agonists (GLP1\u2010RA) to insulin reduced weight and glycemia in people with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective analysis of electronic health records evaluated 296 people with type 1 diabetes over 12\u2009months after medications were first prescribed. Four groups were defined: control\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200980, SGLT2i\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200994, GLP1\u2010RA\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200982, and combination of drugs (Combo)\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200940. We measured\u00a0changes at 1\u00a0year in weight and glycated hemoglobin (HbA1c).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The control group did not have changes in weight or glycemic control. The mean (SD) percentage weight loss after 12\u2009months was 4.4%\u00a0(6.0%), 8.2%\u00a0\u2009(8.5%), and 9.0%\u00a0(8.4%) in the SGLT2i, GLP1\u2010RA, and Combo groups, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001). The Combo group lost the most weight (\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u00a00.001). The HbA1c reduction was 0.4%\u2009\u2009(0.7%), 0.3%\u2009(0.7%), and 0.6%\u2009(0.8%) in the SGLT2i, GLP1\u2010RA, and Combo groups, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001). The Combo group had the biggest improvements in glycemic control and total and low\u2010density lipoprotein cholesterol compared with baseline (all\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u00a00.01). Severe adverse events were similar between all the groups, with no increased risk of diabetic ketoacidosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The SGLT2i and GLP1\u2010RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.23677","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T03:23:36Z","timestamp":1677036216000},"page":"716-723","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Glucagon\u2010like peptide\u20101 agonists combined with sodium\u2010glucose cotransporter\u20102 inhibitors reduce weight in type 1 diabetes"],"prefix":"10.1002","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-4369","authenticated-orcid":false,"given":"Ebaa","family":"Al\u2010Ozairi","sequence":"first","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"},{"name":"Department of Medicine, Faculty of Medicine Kuwait University Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-0221","authenticated-orcid":false,"given":"Mohammad","family":"Irshad","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etab","family":"Taghadom","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litty","family":"Sojan","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumana","family":"Al Kandari","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dherar","family":"Alroudhan","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[{"name":"Diabetes Complications Research Center, UCD Conway Institute University College Dublin School of Medicine Dublin Ireland"},{"name":"Diabetes Research Centre Ulster University Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7425925"},{"key":"e_1_2_10_5_1","first-page":"145","article-title":"Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control","volume":"38","author":"McCall AL","year":"2013","journal-title":"Minerva Endocrinol"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"issue":"4","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"4s51","DOI":"10.1016\/S1262-3636(05)88268-0","article-title":"Weight gain and insulin treatment","volume":"31","author":"Larger E","year":"2005","journal-title":"Diabetes Metab"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4671-6"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.077487"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2977"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.012"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800101-1.00002-8"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.02.014"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0691"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14532"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0623"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1087"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0343"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP13065.OR"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz179"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e318279b7d6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30154-8"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1749"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1584"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1136"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12982"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2338"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0006"},{"key":"e_1_2_10_32_1","first-page":"291","article-title":"Impact of Dose Adjustment for Normal eating (DAFNE) courses on glycemia, incidence of severe hypoglycemia, and episodes of diabetic ketoacidosis in people with type 1 diabetes [abstract]","volume":"48","author":"Taghadom E","year":"2022","journal-title":"Sci Diabetes Self Manag Care"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12441"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.17925\/EE.2021.17.1.12","article-title":"Dapagliflozin as an adjunct therapy to insulin in patients with type 1 diabetes mellitus: efficacy and safety of this combination","volume":"17","author":"Jendle JH","year":"2021","journal-title":"TouchREV Endocrinol"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0078"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0690"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207018"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.23677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.23677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.23677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T06:19:17Z","timestamp":1701929957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.23677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/oby.23677"],"URL":"https:\/\/doi.org\/10.1002\/oby.23677","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"2022-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}